Foster City, CA, United States of America

Anna Zagorska

USPTO Granted Patents = 7 

Average Co-Inventor Count = 6.4

ph-index = 3

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2023-2024

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Anna Zagorska: Innovator in LPA Receptor Antagonists

Introduction

Anna Zagorska is a prominent inventor based in Foster City, CA (US). She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target Lysophosphatidic Acid Receptor 1 (LPAR1). With a total of 7 patents to her name, her work is paving the way for new treatments for various diseases.

Latest Patents

Among her latest patents are two notable inventions related to LPA receptor antagonists. The first patent focuses on compounds that bind to LPAR1 and act as antagonists. This disclosure highlights the potential use of these compounds in preparing medicaments for treating diseases such as fibrosis and liver conditions, including non-alcoholic steatohepatitis (NASH). The second patent reiterates similar findings, emphasizing the therapeutic applications of these compounds in combating the same diseases.

Career Highlights

Anna Zagorska is currently employed at Gilead Sciences, Inc., where she continues to innovate and develop new therapeutic solutions. Her expertise in medicinal chemistry and her dedication to research have established her as a key figure in her field.

Collaborations

Throughout her career, Anna has collaborated with esteemed colleagues, including Kin Shing Yang and Barton W Phillips. These partnerships have further enhanced her research and contributed to the advancement of her projects.

Conclusion

Anna Zagorska's work in developing LPA receptor antagonists represents a significant advancement in the treatment of serious medical conditions. Her innovative spirit and dedication to research continue to inspire progress in the field of medicinal chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…